Search

Your search keyword '"Melia M"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Melia M" Remove constraint Author: "Melia M" Publisher elsevier bv Remove constraint Publisher: elsevier bv
19 results on '"Melia M"'

Search Results

1. Machine-to-machine variability of roughness and corrosion in additively manufactured 316L stainless steel

2. 1098P Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.

3. 1090P HER2 copy number variation in non-small cell lung cancer (NSCLC)

4. 184P Association of tumor-associated neutrophils (TAN) with immunotherapy outcomes in patients in advanced non-small cell lung cancer

5. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

6. 1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy

7. 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations

8. 1268P Real-time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC

9. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

10. 1638P Are all leiomyosarcomas created equal? Clinical characteristics and experience of a single reference centre

11. Association of immune-related adverse (irAEs) with immune-checkpoint inhibitors (ICIs) efficacy in solid tumors

12. Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)

13. P2.01-072 Local Management of Oligometastases in Non-Small Cell Lung Cancer (NSCLC)

14. P1.07-028 Determination of Soluble PD-L1 as a Potential Biomarker for Anti-PD(L)1 Therapy in Non-Small Cell Lung Cancer (NSCLC)

16. 478 INFECTIONS DURING PEGINTERFERON (PEGIFN)/RIBAVIRIN (RBV) THERAPY ARE ASSOCIATED WITH THE MAGNITUDE OF DECLINE IN THE LYMPHOCYTE COUNT: RESULTS OF THE IDEAL STUDY

Catalog

Books, media, physical & digital resources